Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0RZLLX
ADC Name
Rituximab-Compound (lc)
Synonyms
Rituximab Compound (lc)
   Click to Show/Hide
Organization
Orum Therapeutics, Inc.
Drug Status
Investigative
Indication
In total 1 Indication(s)
Non Hodgkin lymphoma [ICD11:2B33]
Investigative
Drug-to-Antibody Ratio
8
Structure
Antibody Name
Rituximab
  Antibody Info 
Antigen Name
B-lymphocyte antigen CD20 (MS4A1)
  Antigen Info 
Payload Name
NeoDegrader P4
  Payload Info 
Therapeutic Target
Protein cereblon (CRBN)
  Target Info 
Linker Name
Rituximab-Compound (lc) linker
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
> 50
pM
HL-60 cells
Adult acute myeloid leukemia
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 50.00 pM Positive CD20 expression (CD20+++/++)
Method Description
Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model Adult acute myeloid leukemia HL-60 cells CVCL_0002
References
Ref 1 Neodegrader conjugates; 2021-10-07.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.